Testing a Combination of Vaccines for Cancer Prevention in Lynch Syndrome

• ClinicalTrials.gov Identifier: NCT05419011
• Recruitment Status: Recruiting
• First Posted: June 15, 2022
• Last Update Posted: May 9, 2024
• Sponsor: National Cancer Institute (NCI)
• Information provided by (Responsible Party): National Cancer Institute (NCI)

Tracking Information

• First Submitted Date: June 14, 2022
• First Posted Date: June 15, 2022
• Last Update Posted Date: May 9, 2024
• Actual Study Start Date: May 8, 2023
• Estimated Primary Completion Date: February 1, 2027 (Final data collection date for primary outcome measure)

Current Primary Outcome Measures (submitted: March 14, 2023)

Cumulative incidence rate of the composite endpoint of adenomas (tubular, tubulovillous and serrated), advanced adenomas and colon cancer [ Time Frame: At 104 weeks ]

Will be compared between the two arms using a stratified Cochran-Mantel-Haenszel test where the randomization stratification factors will be included as strata. The cumulative events rates will be reported for each study arm along with the corresponding two-sided 95% confidence intervals.

Original Primary Outcome Measures (submitted: June 14, 2022)

Cumulative incidence rate of the composite endpoint of adenomas (tubular, tubulovillous and serrated), advanced adenomas and colon cancer [ Time Frame: At 104 weeks ]

Will be compared between the two arms using a stratified Mantel-Haenszel test where the randomization stratification factors will be included as strata. The cumulative events rates will be reported for each study arm along with the corresponding two-sided 95% confidence intervals.

Current Secondary Outcome Measures (submitted: June 14, 2022)

• Association of clinical factors with immune responses [ Time Frame: At 104 weeks ]
  Will be evaluated by conducting univariate and multivariate binary regression analyses. These analyses will be conducted for both arms combined (in which case arm is included as a stratification factor in the model) and each arm separately. The proportions of cells within adenomas expressing stem cells markers pre- and post-vaccination will be compared within each study arm using the signed rank test, and within-subject changes will be compared between responders and non-responders using Wilcoxon rank-sum test for each arm separately and both arms combined. Comparisons between study arms will be conducted using a Wilcoxon rank-sum test.
• Incidence of extracolonic neoplasms [ Time Frame: At 104 weeks ]
  Will compare the observed incidences of lynch syndrome (LS)-related extracolonic cancers to historical control incidence of LS-related extracolonic cancers in this patient population. We will collect the information about extracolonic cancers by asking the participants and by reviewing the pathology reports for confirmation.

• Original Secondary Outcome Measures: Same as current

Current Other Pre-specified Outcome Measures (submitted: March 14, 2023)

• Number of antigen-specific T-cells, peripheral blood mononuclear cells (PBMCs), serum soluble factors and antibody levels [ Time Frame: At baseline, 12 weeks, and 56 weeks ]
  Will be log-transformed before conducting any analyses. Comparisons of number of antigen-specific T-cells, PBMCs, serum soluble factors and antibodies between study arms will be conducted using a nonparametric Wilcoxon rank sum test. IgG titers that will be measured serially will be analyzed and compared between the two arms using linear mixed effects models. If zero-inflation is detected, generalized linear mixed models with zero-inflated Poisson or negative binomial distributions will be fitted.
• Prevalence of immune cells markers, tumor associated antigens and stem cell markers [ Time Frame: At baseline, 52 weeks, and 104 weeks ]
  Will be reported using repeated measures techniques. We will also compare pre- and post-vaccination size, number and histology of polyps.
• Differential expression analyses [ Time Frame: At baseline, 52 weeks, and 104 weeks ]
  Will be using Bioconductor R package DESeq2. A paired sample design to compare post- to pre-vaccination samples within each study arm and for both arms combined. Significant genes with Benjamini-Hochberg-adjusted p-value =< 0.05 and absolute value of log2-fold change >= 0.5 will be annotated with pathways of interest in volcano plots.
• Immune cell gene enrichment analysis [ Time Frame: At baseline, 52 weeks, and 104 weeks ]
  Will be calculated using raw read counts with Bioconductor R package GSVA.

Original Other Pre-specified Outcome Measures (submitted: June 14, 2022)

• Number of antigen-specific T-cells, peripheral blood mononuclear cells (PBMCs), serum soluble factors and antibody levels [ Time Frame: At baseline, 12 weeks, and 56 weeks ]
  Will be log-transformed before conducting any analyses. Comparisons of number of antigen-specific T-cells, PBMCs, serum soluble factors and antibodies between study arms will be conducted using a nonparametric Wilcoxon rank sum test. IgG titers that will be measured serially will be analyzed and compared between the two arms using linear mixed effects models. If zero-inflation is detected, generalized linear mixed models with zero-inflated Poisson or negative binomial distributions will be fitted.
• Prevalence of immune cells markers, tumor associated antigens (TAAs) and stem cell markers [ Time Frame: Baseline, 52 weeks, and 104 weeks ]
  Will be reported using repeated measures techniques. We will also compare pre- and post-vaccination size, number and histology of polyps.
• Differential expression analyses [ Time Frame: At baseline, 52 weeks, and 104 weeks ]
  Will be using Bioconductor R package DESeq2. A paired sample design to compare post- to pre-vaccination samples within each study arm and for both arms combined. Significant genes with Benjamini-Hochberg (BH)-adjusted p-value =< 0.05 and absolute value of log2-fold change >= 0.5 will be annotated with pathways of interest in volcano plots.
• Immune cell gene enrichment analysis [ Time Frame: At baseline, 52 weeks, and 104 weeks ]
  Will be calculated using raw read counts with Bioconductor R package GSVA.

Descriptive Information

• Brief Title: Testing a Combination of Vaccines for Cancer Prevention in Lynch Syndrome
• Official Title: A Phase IIB Clinical Trial of the Multitargeted Recombinant Adenovirus 5 (CEA/MUC1/Brachyury) Vaccine (TRI-AD5) and IL-15 Superagonist N-803 in Lynch Syndrome
• Brief Summary: This phase IIb trial tests whether Tri-Ad5 in combination with N-803 works to prevent colon and other cancers in participants with Lynch syndrome. Each of the three injections in Tri-Ad5 vaccine contain a different substance that is in precancer and cancer cells. Injecting these substances may cause the immune system to develop a defense against cancer that recognizes and destroys any precancer and cancer cells that produce these proteins in the future. N-803 may increase immune responses to other vaccines. Giving Tri-Ad5 in combination with immune enhancing N-803 may lower the chance of developing colon and other cancers in participants with Lynch syndrome.

Detailed Description

PRIMARY OBJECTIVE:

I. To evaluate if the combination of trivalent adenovirus-5 (Tri-Ad5) vaccines and IL-15 superagonist nogapendekin alfa inbakicept (N-803) reduces the incidence of colorectal neoplasms in patients with Lynch syndrome (LS).

SECONDARY OBJECTIVES:

I. To evaluate the safety and tolerability of the Tri-Ad5 vaccines + N-803 in combination.

II. To correlate clinical factors such as use of aspirin and non-steroidal anti-inflammatory drugs (NSAID), smoking and alcohol intake with immune responses.

III. To evaluate the effect of Tri-Ad5 vaccines on the incidence of LS-related extracolonic cancers.

IV. To systematically measure the participants' behavior and experience in terms of vaccine uptake, cancer-specific distress and quality of life.

EXPLORATORY OBJECTIVES:

I. To determine the ability of the Tri-Ad5 vaccines + N-803 to generate a 2-fold increase in T cell responses (cell-mediated immunity) at week 12 (early immune response) and at week 56 (long-term memory response).

II. To evaluate circulating anti-MUC1 IgG (antibody-mediated immunity) after Tri-Ad5 vaccines + N-803.

III. To compare the expression of the three tumor associated antigen (TAAs): MUC1, carcinoembryonic antigen (CEA) and brachyury in colorectal neoplasms before and after Tri-Ad5 vaccines + N-803.

IV. To evaluate changes in the immune profile and abundance of resident immune cell types in colonic mucosa after vaccination with Tri-Ad5 vaccines + N-803 using messenger ribonucleic acid sequencing (mRNAseq) and immunohistochemistry (IHC).

V. To test the effects of the vaccines alone or in combination with N-803 on specific immune subsets of peripheral blood mononuclear cells (PBMCs) and serum soluble factors and cytokines.

VI. To compare the expression of stem cell markers in colorectal neoplasms before and after Tri-Ad5 vaccines + N-803.

OUTLINE:

SAFETY PHASE I: Participants receive Tri-Ad5 subcutaneously (SC) at weeks 0, 4, 8, and 52. Participants also undergo standard of care (SOC) colonoscopy with biopsy at baseline, at 52 weeks and 104 weeks.

SAFETY PHASE II: Participants receive Tri-Ad5 SC and N-803 SC at weeks 0, 4, 8, and 52. Participants also undergo SOC colonoscopy with biopsy at baseline, 52 weeks and 104 weeks.

RANDOMIZED CONTROL PHASE: Participants are randomized into 1 of two arms.

ARM I: Participants receive Tri-Ad5 SC and N-803 SC at weeks 0, 4, 8, and 52. Participants also undergo SOC colonoscopy with biopsy at baseline and at 52 and 104 weeks.

ARM II: Participants receive placebo SC at weeks 0, 4, 8, and 52. Participants also undergo SOC colonoscopy with biopsy at baseline and at 52 and 104 weeks.

Participants undergo blood sample collection throughout the study.

• Study Type: Interventional
• Study Phase: Phase 2
• Study Design: Allocation: Randomized; Intervention Model: Parallel Assignment; Masking: Double (Participant, Investigator); Primary Purpose: Prevention
• Condition: Lynch Syndrome

Intervention

• Biological: Adenovirus 5 CEA/MUC1/Brachyury Vaccine Tri-Ad5
  Given SC
  Other Names:

  • Ad5 CEA/MUC1/Brachyury Vaccine Tri-Ad5
  • Ad5-CEA/Ad5-MUC1/Ad5-Brachyury Vaccine Tri-Ad5
  • Adenoviral CEA/MUC1/Brachyury Vaccine Tri-Ad5
  • Tri Ad5
  • Tri-Ad5
  • TriAd5
• Procedure: Biopsy
  Undergo biopsy
  Other Names:

  • BIOPSY_TYPE
  • Bx
• Procedure: Biospecimen Collection
  Undergo blood sample collection
  Other Names:

  • Biological Sample Collection
  • Biospecimen Collected
  • Specimen Collection
• Procedure: Colonoscopy
  Undergo SOC colonoscopy
• Drug: Nogapendekin Alfa
  Given nogapendekin alfa inbakicept (N-803) SC
• Drug: Placebo Administration
  Given SC
• Other: Questionnaire Administration
  Ancillary studies

Study Arms

• Experimental: Arm I (Tri-Ad5, N-803)
  Participants receive Tri-Ad5 SC and N-803 SC at weeks 0, 4, 8, and 52. Participants also undergo SOC colonoscopy with biopsy at baseline and at 52 and 104 weeks. Participants undergo blood sample collection throughout the study.
  Interventions:

  • Biological: Adenovirus 5 CEA/MUC1/Brachyury Vaccine Tri-Ad5
  • Procedure: Biopsy
  • Procedure: Biospecimen Collection
  • Procedure: Colonoscopy
  • Drug: Nogapendekin Alfa
  • Other: Questionnaire Administration
• Placebo Comparator: Arm II (placebo)
  Participants receive placebo SC at weeks 0, 4, 8, and 52. Participants also undergo SOC colonoscopy with biopsy at baseline and at 52 and 104 weeks. Participants undergo blood sample collection throughout the study.
  Interventions:

  • Procedure: Biopsy
  • Procedure: Biospecimen Collection
  • Procedure: Colonoscopy
  • Drug: Placebo Administration
  • Other: Questionnaire Administration
• Experimental: Safety phase I (Tri-Ad5)
  Participants receive Tri-Ad5 SC at weeks 0, 4, 8, and 52. Participants also undergo SOC colonoscopy with biopsy at baseline and at 52 weeks and 104 weeks. Participants undergo blood sample collection throughout the study.
  Interventions:

  • Biological: Adenovirus 5 CEA/MUC1/Brachyury Vaccine Tri-Ad5
  • Procedure: Biopsy
  • Procedure: Biospecimen Collection
  • Procedure: Colonoscopy
  • Other: Questionnaire Administration
• Experimental: Safety phase II (Tri-Ad5 , N-803)
  Participants receive Tri-Ad5 SC and N-803 SC at weeks 0, 4, 8, and 52. Participants also undergo SOC colonoscopy with biopsy at baseline and at 52 weeks and 104 weeks. Participants undergo blood sample collection throughout the study.
  Interventions:

  • Biological: Adenovirus 5 CEA/MUC1/Brachyury Vaccine Tri-Ad5
  • Procedure: Biopsy
  • Procedure: Biospecimen Collection
  • Procedure: Colonoscopy
  • Drug: Nogapendekin Alfa
  • Other: Questionnaire Administration

• Publications *: Not Provided

Recruitment Information

• Recruitment Status: Recruiting
• Estimated Enrollment (submitted: March 14, 2023): 186
• Original Estimated Enrollment (submitted: June 14, 2022): 158
• Estimated Study Completion Date: February 1, 2027
• Estimated Primary Completion Date: February 1, 2027 (Final data collection date for primary outcome measure)

Eligibility Criteria

Inclusion Criteria:

• Participants with LS defined as one of the following:

  • Mutation positive: MLH1, MSH2/EPCAM and MSH6 genotypes with prior history of >= 1 adenoma(s) and/or >= 1 advanced adenoma(s) and/or colon cancer(s) (but no active cancer for 6 months) OR
  • PMS2 genotype with prior history of colon cancer(s) (but no active cancer for 6 months)
• Participants must have at least part of the descending/sigmoid colon and/or rectum intact
• Participants must be at least 6 months from any cancer-directed treatment (such as surgical resection, chemotherapy, immunotherapy or radiation)
• Participants >= 18 years will be enrolled. Because the risk of LS related cancers is very low in participants < 18 years of age, children and adolescents are excluded from this study
• Eastern Cooperative Oncology Group (ECOG) performance status =< 1 (Karnofsky >= 70%)
• Leukocytes >= 3,000/microliter
• Absolute neutrophil count >= 1,500/microliter
• Platelets >= 100,000/microliter
• Total bilirubin within normal institutional limits
• Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 1.5 x institutional upper limit of normal
• Creatinine within normal institutional limits
• The effects of the Tri-Ad5 vaccines and N-803 on the developing human fetus at the recommended therapeutic dose are unknown. For this reason, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her study physician immediately
• Ability to understand and the willingness to sign a written informed consent document
• Participants must be willing and able to space coronavirus disease (COVID) vaccines at least 2 weeks prior to and 2 weeks after receipt of study agent

Exclusion Criteria:

• History of organ allograft or other history of immunodeficiency
• Known human immunodeficiency virus (HIV) with CD4 count < 540, hepatitis B virus (HBV), or hepatitis C virus (HCV) infection. Subjects with laboratory evidence of cleared HBV and HCV infection will be permitted. Poorly controlled HIV may prevent an adequate immune response to the vaccine and will be an exclusion criterion
• Subjects requiring systemic treatment with corticosteroids (> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 3 months of vaccination
• Participants may not be receiving any other investigational agents
• History of allergic reactions attributed to compounds of similar chemical or biologic composition to adenovirus-based vaccines and N-803
• Uncontrolled intercurrent illness or psychiatric illness/social situations that would limit compliance with study requirements
• Pregnant women are excluded from this study because of the unknown effects of the vaccine and N-803 on the fetus. Because there is an unknown but potential risk for adverse events (AEs) in nursing infants secondary to treatment of the mother with the vaccine plus N-803, breastfeeding should be discontinued if the mother is treated with the vaccine plus N-803
• History of untreated thrombotic disorders
• Participants who experienced severe side effects or allergic reactions to previous adenovirus-based vaccines (such as Johnson and Johnson COVID vaccine) will be excluded

Sex/Gender

• Sexes Eligible for Study: All

• Ages: 18 Years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Listed Location Countries: Puerto Rico, United States

Administrative Information

• NCT Number: NCT05419011
• Other Study ID Numbers: NCI-2021-14234; NCI-2021-14234 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) ); NCI 21-05-01; NCI21-05-01 ( Other Identifier: Northwestern University ); INT21-05-01 ( Other Identifier: DCP ); P30CA060553 ( U.S. NIH Grant/Contract ); UG1CA242596 ( U.S. NIH Grant/Contract ); UG1CA242609 ( U.S. NIH Grant/Contract ); UG1CA242632 ( U.S. NIH Grant/Contract ); UG1CA242635 ( U.S. NIH Grant/Contract ); UG1CA242643 ( U.S. NIH Grant/Contract )
• Has Data Monitoring Committee: Yes

U.S. FDA-regulated Product

• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No

IPD Sharing Statement

• Plan to Share IPD: Yes
• Plan Description: 'NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page'
• URL: https://grants.nih.gov/policy/sharing.htm

• Current Responsible Party: National Cancer Institute (NCI)
• Original Responsible Party: Same as current
• Current Study Sponsor: National Cancer Institute (NCI)
• Original Study Sponsor: Same as current
• Collaborators: Not Provided

Investigators

• Principal Investigator: Ajay Bansal; University of Kansas

• PRS Account: National Cancer Institute (NCI)
• Verification Date: April 2024